Colorectal Omics and ofCS Proteoglycans (COCO) in Screening and a Diagnostic Pathway
Observational · No treatment assigned · 2 sites · Nordsjaellands Hospital
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Colorectal Cancer, Colorectal Adenoma and Inflammatory Bowel Disease (IBD). This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
Some of the main requirements, copied from the record:
- Patients planned to undergo a colonoscopy either as part of the colorectal cancer screening programme due to a positive FIT or within a 'cancer patient pathway' for CRC at one of the study sites.
- Able to speak Danish, English, or other languages with sufficient interpretation provided by relatives.
- Able to give informed consent
There are also 3 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 2000 participants are expected to take part.
- Start date: 2026-08-11.
- Main results expected around 2029-11-30 (estimate from the record).
- 2 study sites listed (2 marked recruiting) in Denmark.
Main thing being measured
- Colorectal cancer (30 days)
In the researchers’ words
Colorectal Cancer (CRC), or bowel cancer, is a serious disease that affects many people globally. The earlier CRC is diagnosed, the better the patient outcomes.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Colorectal Cancer; Colorectal Adenoma; Inflammatory Bowel Disease (IBD) |
| Lead sponsor | Nordsjaellands Hospital |
| Enrollment | 2000 (estimated) |
| Start date | 2026-08-11 |
| Primary completion (est.) | 2029-11-30 |
| First posted | 2025-11-20 |
| Last updated | 2026-08-24 |
| Official title | Colorectal OmiCs and Oncofetal Chondroitin Sulfate-modified Proteoglycans in Screening and Colorectal Cancer Diagnostic Pathway |
| ClinicalTrials.gov ID | NCT07237984 |
Interventions
- Blood sampling (Diagnostic Test)
Analyses of ofCS proteoglycans, proteomics (proteins), metabolomics (metabolits) and other biomarkers. - Stool samplong (Diagnostic Test)
Fecal immunochemical test (FIT), feces sampled by the participant
Full eligibility criteria (from the record)
Inclusion Criteria: * Patients planned to undergo a colonoscopy either as part of the colorectal cancer screening programme due to a positive FIT or within a 'cancer patient pathway' for CRC at one of the study sites. * Able to speak Danish, English, or other languages with sufficient interpretation provided by relatives. * Able to give informed consent Exclusion Criteria: * Patients previously included in the study * Patients known to be pregnant (pregnancy test not required) * Non-resident in Denmark.
Locations (2)
| Site | City | Country | Site status |
|---|---|---|---|
| Copenhagen University Hospital - North Zealand | Hillerød | Denmark | Recruiting |
| Copenhagen University Hospital - Amager-Hvidovre | Hvidovre | Denmark | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.